Urinary RNA-based biomarkers for prostate cancer detection

Area of Science:

• Oncology
• Molecular Diagnostics
• Urology

Background:

• Prostate cancer (PCa) is a leading male malignancy globally.
• Serum prostate-specific antigen (PSA) is a key biomarker but lacks specificity, leading to false positives.
• Improved diagnostic tools are needed to avoid unnecessary prostate biopsies.

Purpose of the Study:

• To review the potential of urinary RNA-based biomarkers for PCa detection.
• To highlight RNA biomarkers as a non-invasive alternative for diagnosing urological malignancies.
• To assess the utility of various RNA types (mRNA, lncRNA, miRNA) and algorithms for PCa diagnosis.

Main Methods:

• Literature review of studies evaluating urinary RNA biomarkers for PCa.
• Analysis of existing approved RNA biomarkers like PCA3.
• Examination of emerging RNA transcripts such as TMPRSS2:ERG, mRNAs, lncRNAs, and miRNAs in urine samples.

Main Results:

• Urine is a viable non-invasive source for detecting urological cancer biomarkers.
• PCA3, a long non-coding RNA, is an FDA-approved urinary biomarker for PCa.
• Various other urinary RNA molecules (TMPRSS2:ERG, mRNAs, lncRNAs, miRNAs) show diagnostic potential.

Conclusions:

• Urinary RNA biomarkers represent a significant advancement in non-invasive PCa diagnostics.
• Validation of specific RNA markers or algorithms can improve PCa detection accuracy.
• These biomarkers may help reduce the need for invasive prostate biopsies.